Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings Of The Fortnight: IPOs Dominate Early 2014 With 13 Debuts In As Many Days

This article was originally published in The Pink Sheet Daily

Executive Summary

Insider participation continues to play an important role in getting a majority of biotech IPOs off the ground; and it’s not clear if or when that trend will change. Plus, news on recent financings by Dicerna, uniQure, Lumos Pharma and NightstaRx.

You may also be interested in...



How And Why Genzyme And Alnylam Expanded Their Alliance

Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.

uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.

UniQure’s Glybera Is First Gene Therapy Okayed In Western Europe

UniQure’s Glybera (alipogene tiparvovec) has become the first gene therapy to be approved for commercialization in the 27-nation European Union, marking a major step towards making such medicines available for treating rare diseases that have a high unmet medical need.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel